Emergence of a scientific and commercial research and development infrastructure for human gene therapy

Human Gene Therapy

Volumn 16, Issue 2, 2005, Pages 169-177

  Crofts, Christine ^a   Krimsky, Sheldon ^b  

^a BOSTON COLLEGE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DNA MODIFICATION; GENE THERAPY; IMMUNOTHERAPY; PATENT; PUBLICATION; RESEARCH; REVIEW; SOMATIC CELL; UNITED STATES;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

BIOMEDICAL RESEARCH; BIOTECHNOLOGY; COMMERCE; GENE THERAPY; GENETIC DISEASES, INBORN; HUMANS;

EID: 14844293113     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.169     Document Type: Review

References (37)

1. ANDERSON, W.F. (1990). Why start a new journal on human gene therapy? [editorial]. Hum. Gene Ther. 1, 1.
2. ANDERSON, W.F. (2003). History of gene therapy. Available at URL http://www.frenchanderson.org/history/history.asp (accessed February 2005).
3. BEGLEY, S., and HAGER, M. (1989). Brave new gene therapy. Newsweek, February 13. p. 65.
4. BERNS, A. (2004). Good news for gene therapy. N. Engl. J. Med. 350, 1679-1680.
5. BRADY, D. (1990). Signals of hope (Gene therapy may cure cystic fibrosis). Maclean's Magazine. October 1, p. 52.
6. BROWNLEE, S., and SILBERNER, J. (1991). The age of genes. U.S. News & World Report, November, p. 64.
7. BRUNETTI-PIERRI, N., PALMER, D.J., BEAUDET, A.L., CAREY, K.D., FINEGOLD, M., and NG, P. (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15, 35-46.
8. CAPRON, A.M. (1990). The impact of the report, Splicing Life. Hum. Gene Ther. 1, 69-71.
9. CAREY, J. (1990). Cells that carry messengers of health. Business Week, May 28, p. 74.
10. CAVAZZANA-CALVO, M., THRASHER, A., and MAVILIO, F. (2004). The future of gene therapy. Nature 427, 779-781.
11. CHECK, E. (2004). Gene therapists hopeful as trials resume with childhood disease. Nature 429, 587.
12. CHECK, E. (2005). Gene therapy put on hold as third child develops cancer. Nature 433, 561.
13. CRANE, D. (1972). Invisible Colleges: Diffusion of Knowledge in Scientific Communities (University of Chicago Press, Chicago).
14. FRIEND, T. (1990). New frontier: Designer genes take on cancer; treatment takes battle inside body. USA Today, October 30, p. 1A.
15. GAU, G., LEBHERZ, C., WEINER, D.J., GRANT, R., CALCEDO, R., MCCULLOUGH, B., BAGG, A., ZHANG, Y., and WILSON, J.M. (2004). Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103, 3300-3302.
16. GENE THERAPY WEEKLY. (2003). Severe combined immunodeficiency: Scientists discover cause of leukemia that halted treatment trial for X SCID. November 6. p. 29.
17. JAIN, K.K. (2000). Special Report on Gene Therapy Companies (John Wiley & Sons, Chichester, UK).
18. JOURNAL OF GENE MEDICINE. (2004). Gene therapy clinical trials worldwide. Provided by the Journal of Gene Medicine and available at URL www.wiley.co.uk/wileychi/genmed/clinical (accessed February 2005).
19. LYON, J., and GORNER, P. (1995). Altered Fates: Gene Therapy and the Retooling of Human Life (W.W. Norton, New York).
20. MACER, D.R.J., AKIYAMA, S., ALORA, A.T., ASADA, Y., AZARIAH, J., AZARIAH, H., BOOST, M.V., CHATWACHIRAWONG, P., KATO, Y., KAUSHIK, V., et al. (1995). International perceptions and approval of gene therapy. Hum. Gene Ther. 6, 791-803.
21. MARTIN, P.A., and THOMAS, S.M. (1996). The Development of Gene Therapy in Europe and the United States: A Comparative Analysis, pp. 69-78. STEEP Special Report No. 5 (University of Sussex Science Policy Research Unit, Brighton, UK).
22. MARTIN, P.A. (1999). Genes as drugs: The social shaping of gene therapy and the reconstruction of genetic disease. Sociol. Health Illness 21, 517-538.
23. MCCORMACK, M.P., and RABBITTS, T.R. (2004). Mechanisms of disease: Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913-922.
24. MCGINN, R.E. (1991). Science, Technology and Society (Prentice Hall, Englewood Cliffs, NJ).
25. MCNEISH, I., and SECKL, M.J. (2002). Gene therapy approaches for cancer. In Gene Therapy: The Use of DNA as a Drug. Brooks, G., ed. (London: Pharmaceutical Press).
26. NATIONAL INSTITUTES OF HEALTH. (2003). Clinical Trials website. Available at URL www.clinicaltrials.gov (accessed February 2005).
27. NELKIN, D. (1996). Covering gene therapy: Beware the hype. Quill 84, 34-36. (Available at www.FACSNET.org)
28. NICHOLS, E.K. (1988). Human Gene Therapy (Harvard University Press. Cambridge, MA).
29. ORKIN, S.H., and MOTULSKY, A.C. (1995). Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Available at URL http://www.nih.gov/news/panelrep.html (accessed February 2005).
30. PRESIDENT'S COMMISSION FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL AND BEHAVIORAL RESEARCH. (1982). Splicing Life: The Social and Ethical Issues of Genetic Engineering with Human Beings (U.S. Government Printing Office, Washington, D.C.) p. 44.
31. RECOMBINANT DNA ADVISORY COMMITTEE. (2003). Clinical Trials in Human Gene Transfer (protocol list). Available at URL http://www4.od.nih.gov/oba/rac/ clinicaltrial.htm (accessed February 2005).
32. STOLBERG, S.G. (1999). Five questions: The long horizon of gene therapy. New York Times, December 12, Section 3, p. 4.
33. THE LANCET. (2004). Efficacy of gene therapy for SCID is being confirmed. [Editorial]. 364, 2155.
34. THOMPSON, L. (1994). Correcting the Code: Inventing the Genetic Cure for the Human Body (Simon & Schuster, New York).
35. TURNEY, J. (1998). Frankenstein's Footsteps: Science, Genetics and Popular Culture (Yale University Press, New Haven, CT).
36. UNITED STATES PATENT AND TRADEMARK OFFICE. (2003). Patent Full-Text and Full-Page Image Database. Available at URL www.uspto.gov/patft/index.html (accessed February 2005).
37. WADMAN, M. (1995). Hyping results "could damage" gene therapy. Nature 378, 655.